Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …

PD Tamma, SL Aitken, RA Bonomo… - Clinical Infectious …, 2022 - academic.oup.com
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …

Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections

PD Tamma, SL Aitken, RA Bonomo… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …

[HTML][HTML] Global threat of carbapenem-resistant Gram-negative bacteria

SS Jean, D Harnod, PR Hsueh - Frontiers in cellular and infection …, 2022 - frontiersin.org
Infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-
negative bacteria (GNB), including carbapenem-resistant (CR) Enterobacterales (CRE; …

Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections

JP Horcajada, M Montero, A Oliver, L Sorlí… - Clinical microbiology …, 2019 - Am Soc Microbiol
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review

M Nguyen, SG Joshi - Journal of applied microbiology, 2021 - academic.oup.com
Carbapenem is an important therapy for serious hospital‐acquired infections and for the
care of patients affected by multidrug‐resistant organisms, specifically Acinetobacter …

Advances in the microbiology of Stenotrophomonas maltophilia

JS Brooke - Clinical microbiology reviews, 2021 - Am Soc Microbiol
Stenotrophomonas maltophilia is an opportunistic pathogen of significant concern to
susceptible patient populations. This pathogen can cause nosocomial and community …

Clinical challenges treating Stenotrophomonas maltophilia infections: an update

MF Mojica, R Humphries, JJ Lipuma… - JAC-antimicrobial …, 2022 - academic.oup.com
Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has
emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes …

Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach …

S Karakonstantis, EI Kritsotakis, A Gikas - Infection, 2020 - Springer
The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …

[HTML][HTML] Resistance to ceftazidime–avibactam and underlying mechanisms

Y Wang, J Wang, R Wang, Y Cai - Journal of global antimicrobial resistance, 2020 - Elsevier
Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …

Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents

MS Bader, M Loeb, D Leto, AA Brooks - Postgraduate medicine, 2020 - Taylor & Francis
Urinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria are a
growing concern due to limited treatment options. Knowledge of the common uropathogens …